Pfizer Plans For COVID Transition And RSV Vaccine Launch
The COVID-19 vaccine and treatment market is expected to evolve into more a flu-like volume and market in 2023, but will remain a "multi-billion dollar" franchise, Bourla said.
You may also be interested in...
The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.